ICU Medical reports news on its global medical-device business in infusion systems, infusion consumables and high-value critical care products used in hospital, alternate-site and home-care settings. Company updates commonly cover quarterly results, fiscal guidance, GAAP and non-GAAP profitability measures, and revenue trends across the Consumables, Infusion Systems and Vital Care product lines.
Recurring announcements also include earnings-call schedules, investor conference participation and business changes that affect reported comparisons, including the completed divestiture of the IV Solutions business. The company’s news flow centers on product-line performance, margin trends, adjusted EBITDA, adjusted diluted earnings per share and management commentary on operating results.
ICU Medical, Inc. (Nasdaq:ICUI) reported Q3 2020 revenues of $318.6 million, a $11.1 million increase year-over-year. However, GAAP gross profit declined to $113.9 million with a gross margin of 36%, down from 39% in Q3 2019. Net income was $25.0 million, or $1.16 per diluted share, down from $26.6 million or $1.24 per share in the same quarter last year. Adjusted EPS rose to $1.90 from $1.65. The company narrowed its 2020 adjusted EBITDA outlook to $235-$245 million and updated EPS guidance to $6.65-$7.00.
ICU Medical, Inc. (Nasdaq:ICUI) announced its third quarter 2020 earnings release on November 5, 2020, at 4:00 p.m. ET, followed by a conference call at 4:30 p.m. ET. The call can be accessed by dialing (800) 936-9761 with conference ID 9959519 and will also be available via webcast on the company's website. ICU Medical specializes in infusion therapy and critical care products, including IV smart pumps and other innovative medical solutions aimed at enhancing clinical safety and workflow.
ICU Medical, a leader in medical products for infusion therapy and critical care, announced its participation in the Morgan Stanley 18th Annual Global Healthcare Conference scheduled for September 14-18, 2020. The company will present virtually on September 17, 2020, at 12:30 PM Eastern Time. Interested parties can access the live webcast through the company's website under the Investors tab and the Event Calendar section. The presentation will also be available for replay.
ICU Medical reported second quarter 2020 revenues of $303.4 million, a decrease from $312.3 million in Q2 2019. The GAAP gross profit rose to $106.3 million, yielding a gross margin of 35%. Net income fell to $18.9 million or $0.88 per diluted share, down from $22.8 million or $1.06 per share a year prior. Adjusted diluted EPS decreased to $1.65 from $1.99. Demand for infusion pumps remained strong amid the COVID-19 pandemic.
ICU Medical, Inc. (Nasdaq:ICUI) announced its Q1 2020 financial results, revealing a revenue of $328.6 million, down from $330.9 million in Q1 2019. The company's GAAP gross profit decreased to $121.4 million, yielding a gross margin of 37% compared to 41% last year. Net income fell to $16.8 million or $0.78 per share, down from $31.0 million or $1.44 per share in the previous year. Adjusted EBITDA also declined to $63.0 million, from $77.9 million. The company revised its full-year guidance for adjusted EBITDA and EPS downward due to external economic factors.